Ibrutinib for Previously Treated Chronic Lymphocytic Leukaemia and Untreated Chronic Lymphocytic Leukaemia with 17p Deletion or TP53 Mutation (TA429)

Technology Appraisal Guidance No. 429

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Ibrutinib alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults:

  • who have had at least 1 prior therapy or

  • who have a 17p deletion or TP53 mutation, and in whom chemo-immunotherapy is unsuitable and

  • only when the company provides ibrutinib with the discount agreed in the patient access scheme.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at www.nice.org.uk/guidance/ta429

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation

Issue Date: January 2017


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Early emollient use does not prevent eczema in children, studies show

Early emollient use does not prevent eczema in children, studies show

Daily application of emollients in infancy is not effective...

Macrolide prescribing in pregnancy linked to risk of birth defects

Macrolide prescribing in pregnancy linked to risk of birth defects

Researchers have called for caution when prescribing...

Drug shortages - live tracker

Drug shortages - live tracker

Added: Ativan and penicillamine.
Use our constantly...